What is PT-141 (Bremelanotide)?
PT-141, also known as Bremelanotide, is a synthetic peptide from the group of melanocortin agonists, developed as an analogue of α-MSH (α-Melanocyte-Stimulating Hormone). In Studies have observed activation of the melanocortin receptors MC3R and MC4R in the central nervous system, which is associated with regulation of sexual function, energy balance, and neuroendocrine response.
PT-141 differs from Melanotan II in that it primarily targets central neuroregulation rather than peripheral effects such as melanogenesis. In research settings, it has been used as a model to study neuromodulation of sexual behavior, vasodilation, and the hypothalamic-pituitary axis, as well as a potential link to libido and mood.
Observations on PT-141
In the scientific literature, PT-141 has been studied in relation to:
-
Regulation of sexual function - activation of MC4R in the central nervous system
-
Neuromodulation of libido - influencing dopamine and endorphin pathways
-
Effect on vasodilation and blood flow in the genitals
-
Regulation of energy balance and appetite
-
Studies of the melanocortin system and its interaction with other neurotransmitters
-
Potential role in stress adaptation and central fatigue
Scientific data
PT-141 has been studied in preclinical and limited clinical models for its effects on sexual reactivity and neurochemical mechanisms:
-
Activates MC3R and MC4R receptors, leading to stimulation of neuronal pathways associated with libido
-
In live models it has shown improved sexual motivation and frequency of copulatory behaviors
-
Increased sexual interest and arousal observed in human studies
-
Does not directly affect the cardiovascular system or the hormonal levels of GH and IGF-1
-
It is being studied as a potential neuromodulator of the hypothalamic-pituitary axis.
Dosage and administration
The scientific literature on PT-141 typically cites doses between 500 and 2000 μg administered subcutaneously, depending on the study design. Due to its central action, effects occur relatively quickly, within 30 to 120 minutes. Studies have used both single applications and short series.
At 10 mg + 3 ml bacteriostatic water:
Concentration = 3.3 mg/ml → 0.15 ml = 500 μg
Example values:
0.15 ml = 500 μg
0.30 ml = 1 mg
0.45 ml = 1.5 mg
0.60 ml = 2 mg
Possible side effects
In research settings, PT-141 is considered well tolerated. Mild and transient reactions have been reported in published studies, including:
-
mild nausea or dizziness
-
transient increase in blood pressure
-
facial flushing or feeling of warmth
-
changes in sexual motivation in experimental models
-
fatigue or mild drowsiness after application
Most reactions were described as transient, dose-dependent, and resolved within a few hours. No serious adverse effects were reported at study concentrations.
The information is based on scientific publications and is purely educational in nature. It is not intended for the diagnosis, treatment or prevention of disease.